Reuters logo
BRIEF-Dimension Therapeutics says co's board determined proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to "superior proposal"​
2017年9月19日 / 下午12点39分 / 1 个月前

BRIEF-Dimension Therapeutics says co's board determined proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to "superior proposal"​

Sept 19 (Reuters) - Dimension Therapeutics Inc

* Dimension Therapeutics - ‍Dimension board determines proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to “superior proposal”​

* Dimension Therapeutics -‍co’s board has not determined ultragenyx’s proposal in fact constitutes superior proposal under existing deal with Regenxbio​

* Dimension Therapeutics Inc - board has not changed its recommendation in support of merger with Regenxbio​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below